抗体药物偶联物 (ADC) 具有较高的特异性和较小的脱靶效应，因此比传统化疗具有更高的疗效。美国食品药品监督管理局 (FDA) 已批准总共 14 种 ADC 用于抗癌，目前有超过 100 种 ADC 正在进行临床试验。特别令人感兴趣的是针对免疫抗原 PD-L1、B7-H3、B7-H4 和整合素的 ADC。具体来说，我们描述了正在开发的 ADC 以及这些免疫检查点在多种癌症类型中的基因和蛋白质表达。让 url = window.clickTag || window.clickTag1 || window.clickTag2 || window.clickTag3 || window.clickTag4 || window.bsClickTAG || window.bsClickTAG1 || window.bsClickTAG2 ||窗口.url || ''; if(typeof url == 'string'){ document.body.dataset['perxceptAdRedirectUrl'] = url;}.版权所有 © 2024 Elsevier B.V. 保留所有权利。

Antibody-drug conjugates (ADCs) have high specificity with lesser off-target effects, thus providing improved efficacy over traditional chemotherapies. A total of 14 ADCs have been approved for use against cancer by the US Food and Drug Administration (FDA), with more than 100 ADCs currently in clinical trials. Of particular interest ADCs targeting immune antigens PD-L1, B7-H3, B7-H4 and integrins. Specifically, we describe ADCs in development along with the gene and protein expression of these immune checkpoints across a wide range of cancer types. let url = window.clickTag || window.clickTag1 || window.clickTag2 || window.clickTag3 || window.clickTag4 || window.bsClickTAG || window.bsClickTAG1 || window.bsClickTAG2 || window.url || ''; if(typeof url == 'string'){ document.body.dataset['perxceptAdRedirectUrl'] = url;}.Copyright © 2024 Elsevier B.V. All rights reserved.